Comparison of QuPath and HALO Platforms for Analysis of the Tumor Microenvironment in Prostate Cancer

QuPath和HALO平台在分析前列腺癌肿瘤微环境方面的比较

阅读:2

Abstract

QuPath, an open-source digital pathology platform, has gained widespread use for image analysis in biomedical research since its release in 2016. However, its reproducibility and reliability compared with commercial software, such as HALO, require further validation, particularly for multiplex immunofluorescence analysis. In this study, we performed a direct comparison of QuPath and HALO using a multiplex immunofluorescence-stained prostate cancer tissue microarray inclusive of 192 unique cores. We evaluated performance across 3 key analytical modules: immune cell phenotyping, tumor infiltration with immune cells, and nearest neighbor analysis. Furthermore, we integrated QuPath with CytoMap, an open-source spatial analysis tool, to perform unsupervised clustering of immune cell infiltration-a feature not available in HALO. Our results demonstrated high concordance between 2 platforms, with correlation coefficients >0.89 for immune cell density, distance, and pattern of cell organization in tumor microenvironment. A neighborhood analysis using CytoMap was further performed and provided a more detailed spatial analysis of immune cell distribution across different prostate cancer grades. A significant increase of CD103+ T-cell infiltration into tumor microenvironment was observed in prostate cancer. In conclusion, our findings validate QuPath as a robust and reproducible alternative to commercial platforms for fluorescence-based digital pathology. By demonstrating QuPath's capability to perform high-quality quantitative analysis with additional flexibility for integration with external tools, our study underscores its potential for advancing tumor microenvironment research in translational oncology.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。